(Q38017388)

27 August 2017

title

Flaviviruses and flavivirus vaccines (English)

1 reference

27 August 2017

1 reference

2

Karin Stiasny

1 reference

27 August 2017

Franz X Heinz

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

30

1 reference

27 August 2017

issue

29

1 reference

27 August 2017

page(s)

4301-4306

1 reference

Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Emerging vector-borne flavivirus diseases: are vaccines the solution?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Dengue: a continuing global threat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Progress towards a dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

7 January 2021

Pathogenic flaviviruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Japanese encephalitis: new options for active immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

7 January 2021

Tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

The continuing spread of West Nile virus in the western hemisphere

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Epidemiology and transmission dynamics of West Nile virus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

West Nile virus: a growing concern?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Structure of the immature dengue virus at low pH primes proteolytic maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Association of the pr Peptides with Dengue Virus at Acidic pH Blocks Membrane Fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Structures of immature flavivirus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Structure of West Nile Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Molecular mechanisms involved in the early steps of flavivirus cell entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Flavivirus membrane fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Immature Dengue Virus: A Veiled Pathogen?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

A ligand-binding pocket in the dengue virus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Crystal Structure of West Nile Virus Envelope Glycoprotein Reveals Viral Surface Epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Conformational changes of the flavivirus E glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Crystal Structure of the West Nile Virus Envelope Glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Membrane interactions of the tick-borne encephalitis virus fusion protein E at low pH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Characterization of a Structural Intermediate of Flavivirus Membrane Fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

The structural immunology of antibody protection against West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Structural basis of West Nile virus neutralization by a therapeutic antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Impact of Quaternary Organization on the Antigenic Structure of the Tick-Borne Encephalitis Virus Envelope Glycoprotein E

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Epitope Determinants of a Chimpanzee Dengue Virus Type 4 (DENV-4)-Neutralizing Antibody and Protection against DENV-4 Challenge in Mice and Rhesus Monkeys by Passively Transferred Humanized Antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Humanized Monoclonal Antibodies Derived from Chimpanzee Fabs Protect against Japanese Encephalitis Virus In Vitro and In Vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Prospects for a virus non-structural protein as a subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Antibody Recognition of Cell Surface-Associated NS1 Triggers Fc- Receptor-Mediated Phagocytosis and Clearance of West Nile Virus-Infected Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Cryptic Properties of a Cluster of Dominant Flavivirus Cross-Reactive Antigenic Sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Maturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated Neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

An inactivated cell-culture vaccine against yellow fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

New Japanese encephalitis vaccines: alternatives to production in mouse brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Field effectiveness of vaccination against tick-borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Global spread and persistence of dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Antibody-mediated neutralization of flaviviruses: a reductionist view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Partial maturation: an immune-evasion strategy of dengue virus?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Recent advancement in flavivirus vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

Dengue vaccines: progress and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.114

10.1016/J.VACCINE.2011.09.114

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference